[1]竇冬冬,張易青.EZH2與乳腺癌及其抑制劑研究[J].醫學信息,2020,(04):47-50.[doi:10.3969/j.issn.1006-1959.2020.04.015]
 DOU Dong-dong,ZHANG Yi-qing.EZH2 and Breast Cancer and its Inhibitors[J].Medical Information,2020,(04):47-50.[doi:10.3969/j.issn.1006-1959.2020.04.015]
點擊復制

EZH2與乳腺癌及其抑制劑研究()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2020年04期
頁碼:
47-50
欄目:
綜述
出版日期:
2020-02-15

文章信息/Info

Title:
EZH2 and Breast Cancer and its Inhibitors
文章編號:
1006-1959(2020)04-0047-04
作者:
竇冬冬張易青
(青海大學附屬醫院病理科,青海 西寧 810000)
Author(s):
DOU Dong-dongZHANG Yi-qing
(Department of Pathology,the Affiliated Hospital of Qinghai University,Xining810000,Qinghai,China)
關鍵詞:
乳腺癌EZH2EZH2抑制劑
Keywords:
Breast cancerEZH2EZH2 inhibitors
分類號:
R737.9
DOI:
10.3969/j.issn.1006-1959.2020.04.015
文獻標志碼:
A
摘要:
乳腺癌作為女性最常見的腫瘤,其生存率和生存質量往往不能令人滿意。目前,眾多研究表明乳腺癌的發生、發展機制受到表觀遺傳修飾的高度影響。果蠅zest基因增強子同源物2(EZH2)作為一種組蛋白甲基轉移酶,通過催化組蛋白H3第27位賴氨酸殘基(H3K27)的三甲基化參與細胞周期調控、分化和沉默相關靶基因的轉錄,進而促進腫瘤的發生。目前發現EZH2在多種腫瘤中過表達并與腫瘤的侵襲和預后密切相關,且對EZH2抑制劑的研究已進入臨床試驗階段。因此,本文對EZH2在乳腺癌中的作用機制及EZH2抑制劑的研究現狀作一綜述,旨在為乳腺癌的臨床治療提供參考依據。
Abstract:
Breast cancer is the most common tumor in women, and its survival rate and quality of life are often unsatisfactory. At present, many studies have shown that the genesis and development mechanism of breast cancer are highly affected by epigenetic modification. Drosophila zest gene enhancer homolog 2 (EZH2), as a histone methyltransferase, participates in cell cycle regulation and differentiation by catalyzing the trimethylation of histone H3 lysine residue (H3K27) at position 27 and silence the transcription of related target genes, which in turn promotes tumorigenesis. EZH2 has been found to be over-expressed in many tumors and is closely related to tumor invasion and prognosis, and research on EZH2 inhibitors has entered clinical trials. Therefore, this article reviews the mechanism of EZH2 in breast cancer and the research status of EZH2 inhibitors, in order to provide a reference for the clinical treatment of breast cancer.

參考文獻/References:

[1]Miller KD,Siegel RL,Lin CC,et al.Cancer treatment and survivorship statistics,2016[J].CA Cancer J Clin,2016,66(4):271-289. [2]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].A Cancer Journal for Clinicians,2016,66(2):115-132. [3]Zhou S,Sun X,Yu L,et al.Differential expression and clinical significance of epithelial-mesenchymal transition markers among different histological types of triple-negative breast cancer[J].J Cancer,2018,9(3):604-613. [4]Shao M,Liu Y,Zhang Y,et al.EZH2 Correlations of and gene polymorphisms with breast cancer susceptibility and prognosis[J].BiosciRep,2018(38):undefined. [5]Ishak CA,Marshall AE,Passos DT,et al.An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences[J].Molecular cell,2016,64(6):1074-1087. [6]Bae WK,Yoo KH,Lee JS,et al.The methyltransferase EZH2 is not required for mammary cancer development,although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers[J].Mol Carcinog,2015,54(10):1172-1180. [7]Rea S,Eisenhaber F,O’Carroll D,et al.Regulation of chromatin structure by site-specific histone H3 methyltransferases[J].Nature,2000,406(6796):593-599. [8]Sims RJ,Nishioka K,Reinberg D.Histone lysine methylation:a signature for chromatin function[J].Trends Genet,2003,19(11):629-639. [9]Cleven AH,Sannaa GAA,Briaire-De Bruijn I,et al.Loss of H3K27 trimethylation is a diagnostic marker for malignant peripheral nerve sheath tumors and indicator for an inferior survival[J].Mod Pathol,2016,29(6):582-590. [10]Husmann Dylan,Gozani Or,Histone lysine methyltransferases in biology and disease[J].Nat. Struct.Mol.Biol,2019,26:880-889. [11]Copeland RA,Solomon ME,Richon VM.Protein methyltransferases as a target class for drug discovery[J].Nat Rev Drug Discov,2009,8(9):724-732. [12]Ueda Minoru,Seki Motoaki,Histone modifications form epigenetic regulatory networks to regulate abiotic stress response[J].Plant Physiol,2019,undefined:undefined. [13]Wu X,Scott H,Carlsson SV,et al.Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy[J].Prostate,2019,79(10):1079-1089. [14]Romanchikova N,Trapencieris P.Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma[J].Anticancer Res,2019,39(8):4179-4184. [15]Yang CC,LaBaff A,Wei Y,et al.Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers[J].Am J Transl Res,2015,7(6):1009-1020. [16]Donaldson-Collier MC,Sungalee S,Zufferey M,et al.EZH2 oncogenic mutations drive epigenetic, transcriptional,and structural changes within chromatin domains[J].Nat Genet,2019,51(3):517-528. [17]Xu J,Wang Z,Lu W,et al.EZH2 promotes gastric cancer cells proliferation by repressing p21 expression[J].Pathol Res Pract,2019,215(6):152374. [18]Guo S,Li X,Rohr J,et al.EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features[J].Diagnostic pathology,2016(11):41. [19]Mu Z,Li H,Fernandez SV,et al.EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells[J].Exp Clin Cancer Res,2013,32(1):70. [20]Collett K,Eide GE,Arnes J,et al.Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer[J].Clin Cancer Res,2006,12(4):1168-1174. [21]Kumari K,Adhya AK,Rath AK,et al.Estrogen-related receptors alpha,beta and gamma expression and function is associated with transcriptional repressor EZH2 in breast carcinoma[J].BMC Cancer,2018(18):690. [22]Batool A,Jin C,Liu YX.Role of EZH2 in cell lineage determination and relative signaling pathways[J].Front Biosci(Landmark Ed),2019(24):947-960. [23]Fujii S,Tokita K,Wada N,et al.MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes[J].Oncogene,2011,30(39):4118-4128. [24]Mohamad Hanif EA,Shah SA.Overview on Epigenetic Re-programming:A Potential Therapeutic Intervention in Triple Negative Breast Cancers[J].Asian Pac J Cancer Prev,2018,19(12):3341-3351. [25]Li Z,Hou P,Fan D,et al.The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer[J].Cell Death Differ,2017,24(1):59-71. [26]Hong F,Zhao M,Zhang L,et al.Inhibition of Ezh2 In Vitro and the Decline of Ezh2 in Developing Midbrain Promote Dopaminergic Neurons Differentiation Through Modifying H3K27me3[J].Stem Cells Dev,2019,28(10):649-658. [27]Chen YT,Zhu F,Lin WR,et al.The novel EZH2 inhibitor,GSK126,suppresses cell migration and angiogenesis via down-regulating VEGF-A[J].Cancer Chemother Pharmacol,2016,77(4):757-765. [28]Qi W,Chan H,Teng L,et al.Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation[J].Proc Natl Acad Sci USA,2012,109(52):21360-21365. [29]Rizq O,Mimura N,Oshima M,et al.Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition[J].Clin Cancer Res,2017,23(16):4817-4830. [30]Souroullas GP,Jeck WR,Parker JS,et al.An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation[J].Nat Med,2016,22(6):632-640. [31]Italiano A,Soria JC,Toulmonde M,et al.Tazemetostat,an EZH2 inhibitor,in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours:a first-in-human,open-label, phase 1 study[J].Lancet Oncol,2018,19(5):649-659. [32]Knutson SK,Kawano S,Minoshima Y,et al.Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma[J].Mol Cancer Ther,2014,13(4):842-854. [33]Chiappella A,Santambrogio E,Castellino A,et al.Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma[J].Expert review of hematology,2017,10(8):697-705. [34]Baker T,Nerle S,Pritchard J,et al.Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors[J].Oncotarget,2015,6(32):32646-32655. [35]Qi W,Zhao K,Gu J,et al.An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED[J].Nat Chem Biol,2017,13(4):381-388.

相似文獻/References:

[1]董 云.SPECT/CT 雙時相99mTc- MIBI斷層顯像 在乳腺癌診斷中的應用[J].醫學信息,2018,(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
 DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Medical Information,2018,(04):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]李建輝,祝旭龍.乳腺癌的治療管理——把好生活質量關[J].醫學信息,2018,(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[3]楊玉峰,李 強,曲國紅,等.乳腺癌術前巴德槍穿刺檢測ER、PR的臨床研究[J].醫學信息,2018,(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
 YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Medical Information,2018,(04):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[4]劉 曼,厲瑪倩倩,徐潤潤,等.延續性護理對乳腺癌術后化療患者生活質量與 健康知識水平的影響[J].醫學信息,2018,(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
 LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Medical Information,2018,(04):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[5]張艷萍,曹 玉,孫國平.服用阿司匹林對乳腺癌患者生存獲益的Meta分析[J].醫學信息,2018,(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
 ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Medical Information,2018,(04):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[6]鐘 磊,謝海燕,林 霖.電化學發光免疫分析技術檢測腫瘤標志物在乳腺癌診斷中的應用[J].醫學信息,2018,(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
 ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Medical Information,2018,(04):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[7]胡平華,黃 勤,李志華.含卡培他濱方案一線或后線治療晚期乳腺癌的效果對比[J].醫學信息,2018,(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
 HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Medical Information,2018,(04):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[8]闕海濤,曹 斌,秦志剛.EGFL7在乳腺癌中的研究進展[J].醫學信息,2018,(23):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
 QUE Hai-tao,CAO Bin,QIN Zhi-gang.Research Progress of EGFL7 in Breast Cancer[J].Medical Information,2018,(04):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
[9]張文婧,宋 冰.HER-2陽性乳腺癌分子靶向治療進展[J].醫學信息,2018,(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
 ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Medical Information,2018,(04):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
[10]張 樂,徐勝昔,郭翔取,等.Tyrer-Cuzick模型聯合SNPs位點在江西地區乳腺癌診斷中應用研究[J].醫學信息,2018,(24):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]
 ZHANG Le,XU Sheng-xi,GUO Xiang-qu,et al.Application of Tyrer-Cuzick Model Combined with SNPs Locus in the Diagnosis of Breast Cancer in Jiangxi Area[J].Medical Information,2018,(04):131.[doi:10.3969/j.issn.1006-1959.2018.24.038]

更新日期/Last Update: 2020-02-15
中国足彩网竞彩 最近涨幅大的股票 大发快三下载网站 海南飞鱼彩票图表 浙江6+1开奖 股票融资融券是什么 安徽快3开奖l结果 加盟股票配资公司 广东体彩十一选五 企鹅乐园秒速赛车计划 吉林体彩11选五的走势图